A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647

NCT05105048 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Cytomegalovirus Infection

Interventions

BIOLOGICAL: mRNA-1647
BIOLOGICAL: Placebo

Sponsor

ModernaTX, Inc.